Doliver Advisors’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $268K | Hold |
3,232
| – | – | 0.07% | 150 |
|
|
2025
Q1 | $262K | Sell |
3,232
-80
| -2% | -$6.49K | 0.07% | 144 |
|
|
2024
Q4 | $298K | Sell |
3,312
-50
| -1% | -$4.5K | 0.08% | 132 |
|
|
2024
Q3 | $332K | Sell |
3,362
-100
| -3% | -$9.88K | 0.09% | 119 |
|
|
2024
Q2 | $321K | Buy |
3,462
+1,100
| +47% | +$102K | 0.09% | 117 |
|
|
2024
Q1 | $224K | Sell |
2,362
-50
| -2% | -$4.74K | 0.06% | 136 |
|
|
2023
Q4 | $215K | Buy |
+2,412
| New | +$215K | 0.07% | 138 |
|
|
2023
Q3 | – | Sell |
-2,537
| Closed | -$211K | – | 165 |
|
|
2023
Q2 | $211K | Sell |
2,537
-175
| -6% | -$14.6K | 0.06% | 157 |
|
|
2023
Q1 | $207K | Sell |
2,712
-413
| -13% | -$31.5K | 0.06% | 154 |
|
|
2022
Q4 | $259K | Sell |
3,125
-15
| -0.5% | -$1.25K | 0.09% | 126 |
|
|
2022
Q3 | $249K | Sell |
3,140
-587
| -16% | -$46.5K | 0.09% | 124 |
|
|
2022
Q2 | $277K | Buy |
3,727
+437
| +13% | +$32.5K | 0.1% | 130 |
|
|
2022
Q1 | $296K | Buy |
+3,290
| New | +$296K | 0.09% | 135 |
|